Partner Therapeutics Announces FDA Approval of BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner's National Priority Voucher

First Targeted Therapy Approved for NRG1+ Cholangiocarcinoma BIZENGRI Now Approved for Patients Harboring NRG1 Gene Fusions in Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, and Cholangiocarcinoma LEXINGTON, Mass., May 11, 2026 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a...